Effectiveness of Rifabutin for Treatment of Helicobacter Pylori
Status:
Not yet recruiting
Trial end date:
2023-07-31
Target enrollment:
Participant gender:
Summary
The aim of this study is to determine the effectiveness of rifabutin triple therapy for the
treatment of H. pylori infection in the Israeli population. Patients with or without a prior
history of H. pylori eradication failure will be randomized to receive one of three possible
treatments:
Group 1-amoxicillin 1000mg bd and rifabutin 150 mg bd and esomeprazole 40 mg bd Group 2-
amoxicillin 1000mg bd and rifabutin 150 mg d and esomeprazole 40 mg bd Group 3- standard of
care